GI Biopharma Overview
- Year Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
1
GI Biopharma General Information
Description
Developer of inflammatory bowel disease (IBD) treatments designed to solve health problems with dysbiosis. The company's treatments for irritable bowel syndrome and other health problems such as ulcerative colitis associated with dysbiosis of gut microbiota target the potential root cause, enabling patients to get rid of inflammatory bowel disease with probiotics and dietary supplements.
Contact Information
Website
www.gi-biopharma.comCorporate Office
- 50 Williams Parkway
- East Hanover, NJ 07936
- United States
Corporate Office
- 50 Williams Parkway
- East Hanover, NJ 07936
- United States
GI Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 01-Jun-2023 | Completed | Clinical Trials - Phase 2 |
GI Biopharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Westfield BioVentures | Accelerator/Incubator | Minority |
GI Biopharma FAQs
-
When was GI Biopharma founded?
GI Biopharma was founded in 2014.
-
Where is GI Biopharma headquartered?
GI Biopharma is headquartered in East Hanover, NJ.
-
What industry is GI Biopharma in?
GI Biopharma’s primary industry is Drug Discovery.
-
Is GI Biopharma a private or public company?
GI Biopharma is a Private company.
-
What is GI Biopharma’s current revenue?
The current revenue for GI Biopharma is .
-
Who are GI Biopharma’s investors?
Westfield BioVentures has invested in GI Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process